DrugPatentWatch Database Preview
Pfizer Company Profile
What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?
There are fifty-three US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand three hundred and eighty-one patent family members on PFIZER drugs in seventy-nine countries and one hundred and fifty-two supplementary protection certificates in fourteen countries.
Summary for Pfizer
| International Patents: | 1381 |
| US Patents: | 53 |
| Tradenames: | 120 |
| Ingredients: | 106 |
| NDAs: | 153 |
| Drug Master File Entries: | 3 |
Drugs and US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | TERRAMYCIN | lidocaine hydrochloride; oxytetracycline | INJECTABLE;INJECTION | 060567-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Pfizer | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-002 | Feb 22, 2005 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Pfizer | GEODON | ziprasidone hydrochloride | CAPSULE;ORAL | 020825-002 | Feb 5, 2001 | AB | RX | Yes | No | 6,150,366 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Pfizer | UNASYN | ampicillin sodium; sulbactam sodium | INJECTABLE;INJECTION | 050608-003 | Dec 31, 1986 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | REVATIO | sildenafil citrate | TABLET;ORAL | 021845-001 | Jun 3, 2005 | 5,250,534*PED | ➤ Sign Up |
| Pfizer | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-001 | Jan 30, 2004 | 5,273,995*PED | ➤ Sign Up |
| Pfizer | NORVASC | amlodipine besylate | TABLET;ORAL | 019787-003 | Jul 31, 1992 | 4,572,909*PED | ➤ Sign Up |
| Pfizer | GLUCOTROL | glipizide | TABLET;ORAL | 017783-001 | May 8, 1984 | 3,669,966 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Tablets | 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg | ➤ Subscribe | 2006-12-29 |
| ➤ Subscribe | Capsules | 200 mg/38 mg | ➤ Subscribe | 2016-02-16 |
| ➤ Subscribe | Capsules | 200 mg/30 mg | ➤ Subscribe | 2004-12-27 |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Sublingual Tablets | 0.3 mg, 0.4 mg and 0.6 mg | ➤ Subscribe | 2005-10-19 |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Tablets | 25 mg and 50 mg | ➤ Subscribe | 2004-11-19 |
| ➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
| ➤ Subscribe | Tablets | 2.5 mg/40 mg | ➤ Subscribe | 2009-09-17 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Tablets | 5 mg/80 mg | ➤ Subscribe | 2009-04-07 |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Tablets | 150 mg and 200 mg | ➤ Subscribe | 2005-11-09 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2004-10-25 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Tablets | 20 mg and 40 mg | ➤ Subscribe | 2010-03-29 |
| ➤ Subscribe | Sublingual Tablets | 0.6 mg | ➤ Subscribe | 2011-12-29 |
Premature patent expirations for PFIZER
Non-Orange Book US Patents for Pfizer
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,001,876 | Isobutylgaba and its derivatives for the treatment of pain | ➤ Sign Up |
| 6,309,671 | Stable glassy state powder formulations | ➤ Sign Up |
| 5,608,090 | GABA and L-glutamic acid analogs for antiseizure treatment | ➤ Sign Up |
| 6,165,463 | Dispersible antibody compositions and methods for their preparation and use | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Pfizer Drugs
Supplementary Protection Certificates for Pfizer Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| /2004 | Austria | ➤ Sign Up | PRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: LI 56370 56371 56372 20031110 |
| C/GB99/024 | United Kingdom | ➤ Sign Up | PRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312 |
| 2014000114 | Germany | ➤ Sign Up | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| C0009 | France | ➤ Sign Up | PRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
